BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 26694595)

  • 21. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials.
    Chen L; Wang G; Zheng F; Zhao H; Li H
    Osteoporos Int; 2015 Sep; 26(9):2355-63. PubMed ID: 25944731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The degree of osteoporosis in patients with vertebral fracture and patients with hip fracture: relationship to incidence of vertebral fracture.
    Takahashi M; Kushida K; Naitou K
    J Bone Miner Metab; 1999; 17(3):187-94. PubMed ID: 10757678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid: A nationwide osteoporosis survey.
    Yu SF; Chen JF; Chen YC; Lai HM; Ko CH; Chiu WC; Su FM; Hsu CY; Su BY; Wu CH; Cheng TT
    Medicine (Baltimore); 2017 Feb; 96(5):e5959. PubMed ID: 28151883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma.
    Dam TT; Harrison S; Fink HA; Ramsdell J; Barrett-Connor E;
    Osteoporos Int; 2010 Aug; 21(8):1341-9. PubMed ID: 19816753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-hip and non-vertebral fractures: the neglected fracture sites.
    Holloway KL; Henry MJ; Brennan-Olsen SL; Bucki-Smith G; Nicholson GC; Korn S; Sanders KM; Pasco JA; Kotowicz MA
    Osteoporos Int; 2016 Mar; 27(3):905-913. PubMed ID: 26438309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low bone mineral density, but not epidural steroid injection, is associated with fracture in postmenopausal women with low back pain.
    Yi Y; Hwang B; Son H; Cheong I
    Pain Physician; 2012; 15(6):441-9. PubMed ID: 23159959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
    Matsumoto T; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Nakano T; Ito M; Tomomitsu T; Hirakawa A; Soen S
    J Bone Miner Metab; 2020 Jul; 38(4):522-532. PubMed ID: 32140784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study.
    Angeli A; Guglielmi G; Dovio A; Capelli G; de Feo D; Giannini S; Giorgino R; Moro L; Giustina A
    Bone; 2006 Aug; 39(2):253-9. PubMed ID: 16574519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ; Naganathan V; Barton I; Grauer A
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone status in glucocorticoid-treated men and women.
    Leib ES; Winzenrieth R
    Osteoporos Int; 2016 Jan; 27(1):39-48. PubMed ID: 26252975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies.
    de Nijs RN; Jacobs JW; Algra A; Lems WF; Bijlsma JW
    Osteoporos Int; 2004 Aug; 15(8):589-602. PubMed ID: 15138667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.
    Ringe JD; Dorst A; Faber H; Ibach K; Preuss J
    Rheumatology (Oxford); 2003 Jun; 42(6):743-9. PubMed ID: 12730532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
    Saag KG; Wagman RB; Geusens P; Adachi JD; Messina OD; Emkey R; Chapurlat R; Wang A; Pannacciulli N; Lems WF
    Lancet Diabetes Endocrinol; 2018 Jun; 6(6):445-454. PubMed ID: 29631782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of oral corticosteroid use on bone mineral density and vertebral fracture.
    Walsh LJ; Lewis SA; Wong CA; Cooper S; Oborne J; Cawte SA; Harrison T; Green DJ; Pringle M; Hubbard R; Tattersfield AE
    Am J Respir Crit Care Med; 2002 Sep; 166(5):691-5. PubMed ID: 12204867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis.
    Oshagbemi OA; Driessen JHM; Pieffers A; Wouters EFM; Geusens P; Vestergaard P; van den Bergh J; Franssen FME; de Vries F
    Osteoporos Int; 2017 Oct; 28(10):2859-2866. PubMed ID: 28638981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Body composition and vertebral fracture risk in female patients treated with glucocorticoid.
    Kaji H; Tobimatsu T; Naito J; Iu MF; Yamauchi M; Sugimoto T; Chihara K
    Osteoporos Int; 2006; 17(4):627-33. PubMed ID: 16437193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Time of Administration of Teriparatide on Bone Mineral Density in Glucocorticoid-Induced Osteoporosis.
    Mastaglia SR
    J Clin Densitom; 2017; 20(4):513-515. PubMed ID: 28579148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between sagittal spinal alignment and the incidence of vertebral fracture in menopausal women with osteoporosis: a multicenter longitudinal follow-up study.
    Dai J; Yu X; Huang S; Fan L; Zhu G; Sun H; Tang X
    Eur Spine J; 2015 Apr; 24(4):737-43. PubMed ID: 25374300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.
    Ringe JD; Dorst A; Faber H; Ibach K; Sorenson F
    Osteoporos Int; 2003 Oct; 14(10):801-7. PubMed ID: 14610641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
    Emkey R; Delmas PD; Goemaere S; Liberman UA; Poubelle PE; Daifotis AG; Verbruggen N; Lombardi A; Czachur M
    Arthritis Rheum; 2003 Apr; 48(4):1102-8. PubMed ID: 12687554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.